RayzeBio

Radiopharmaceuticals Therapy for Cancer

Also Clin1 SCLC; Glypican-3 Clin0 Liver Cancer; 5 add'l RD programs solid tumors

RayzeBio is developing radiopharmaceuticals for cancer treatment. Radiopharmaceutical therapy (RPT) represents a promising novel approach to treat solid tumors. RPT works by selectively delivering radioisotopes to tumors via the bloodstream. Rayze is focusing on alpha and beta radioisotopes, with a preference for using Actinium 225, an alpha radioisotope for therapeutic programs. Importantly, Rayze is also focused on optimizing their target selection and their molecular binders such that the therapies can be agile to allow for deep tumor penetration and be tunable to create drug-like properties for proper clearance from the bloodstream.